FORUM FOSTERS DIALOGUE BETWEEN BREAST CANCER LIVED EXPERIENCE ADVOCATES, RESEARCHERS AND CLINICIANS Organised by the University of Queensland and Translational Research Institute
In October 2024, the Frazier Institute hosted an event dedicated to breast cancer advocacy and research, supported by TRI (Translational Research Institute), National Breast Cancer Foundation, PA Research Foundation, Health Translation Queensland, QUT and The University of Queensland Faculty of Medicine/Frazer Institute.
The key aim of the event co-organised by Associate Professor Joy Wolfram, Group Leader, Australian Institute for Bioengineering and Nanotechnology & School of Chemical Engineering, The University of Queensland was to foster dialogue between breast cancer lived experience advocates (consumers), researchers, and clinicians.
Co-organiser Associate Professor Fernando Guimaraes, Group Leader, Principal Research Fellow, Frazer Institute, The University of Queensland spoke to Australian Health Journal about the need to host the event and regularly engage with consumers.
Jo Maxwell, Principal Project Officer, Consumer and Community Involvement in Research Strategy and Support at The University of Queensland also spoke about the standards for consumer participation and collaboration adopted from the International Association for Public Participation (IAP2).
“IAP2 guides the researcher to structure consumer involvement all through the different stages of their research”, says Maxwell.
Associate Professor Cleola Anderiesz, Chief Executive Officer National Breast Cancer Foundation presented at the Forum and spoke to Australian Health Journal on the impact of engagement when communities, researchers and clinicians come together to hear about the latest research and discuss a future of better breast cancer care and outcomes.
The day long event was enlightening and impactful. The forum in Brisbane included a workshop focused on creating international connections between breast cancer consumers in Australia and the United States, with insights from leading breast cancer oncologists, clinicians, consumers, researchers, and community.
-
Continuity of Care under COVID-19
Series 3, Episode 1
Under the COVID-19 pandemic, the Australian Healthcare system has handled the public health crisis by monitoring and responding to challenges in supply chains, testing & tracing of new infections and stock piling of essential equipment.
The public has largely responded by practising social distancing, understanding how hand hygiene can spread contagion and recently installing the COVIDSafe mobile application. Public health messaging has been largely effective and literacy improve, to combat the dangers of misinformation.
To open up access to medical advice during the pandemic, in March the Australian government issued MBS item codes for telehealth consultations, for advanced practice nurses as well as GPs and other specialists.
According to AMA President Dr Tony Bartone, as of mid-May 2020, around 10 million Medicare-funded telehealth services have been provided, either over the phone or via video, a significant majority of which have been provided by GPs and other specialists since the Medicare telehealth items were introduced in March.
However in recent months, the health system has mounting concerns on:
- a reduction in general practice visits for testing, investigation or immunisation
- lower rates of elective procedures resuming since being halted
- reduction in laboratory testing
- reduction in treatments and diagnosis of chronic and acute conditions
- access to, and continuing to take medications
Those with pre-existing conditions have been urged to keep appointments and routine treatments to maintain their health.
Industry has taken action such as the newly formed Continuity of Care Collaboration (CCC). The 15 health organisations forming CCC are an Australian first national communication collaboration of Peak Bodies, Industry and Healthcare Organisations coming together to stress the importance for people to continue monitoring their health and maintaining their regular care.
This Australian Health Journal episode on the continuity of care was produced with commentary from the following health industry associations and organisations: APNA – Australian Primary Health Care Nurses Association, RACGP, Medical Technology Association of Australia (MTAA), West Cessnock Medical Practice, Consumers Health Forum of Australia, Medicines Australia
-
Stronger patient involvement in new medicines
New strategic agreement between Medicines Industry and Government means stronger patient involvement in new medicines.
Medicines Australia has secured a 5-year Strategic Agreement with the Federal Government, centered on earlier patient involvement and influence in the availability of new medicines in Australia.
-
Improved access to technology needed for people with Type 2 Diabetes needing insulin
The National Diabetes Services Scheme (NDSS) provides subsidised products for diabetes management; however, disparities exist in access to technology between those with Type 1 and Type 2 diabetes. While continuous glucose monitoring (CGM) devices are subsidised for Type 1, they are not available for Type 2 diabetes. ADEA advocates for equitable access to these essential tools, emphasising that all individuals with diabetes deserve the resources necessary for optimal management and reduced risk of complications. Without such technologies, many are forced to rely on finger pricking, which can be inconvenient and unsafe in settings such as the workplace and in higher education.
